Published in Circulation on November 01, 1985
Peripheral neutrophil inclusions in amiodarone treated patients. Br J Clin Pharmacol (1986) 0.95
Plasma protein binding of amiodarone in a patient population: measurement by erythrocyte partitioning and a novel glass-binding method. Br J Clin Pharmacol (1988) 0.81
Amiodarone induced pulmonary toxicity: An unusual response to steroids. Am J Case Rep (2012) 0.78
Antioxidant activity of amiodarone on human lipoprotein oxidation. Br J Pharmacol (2001) 0.78
A case of amiodarone-associated pulmonary toxicity. Korean J Intern Med (1995) 0.77
Amiodarone concentrations in plasma and fat tissue during chronic treatment and related toxicity. Br J Clin Pharmacol (2009) 0.75
EEA1 links PI(3)K function to Rab5 regulation of endosome fusion. Nature (1998) 7.92
North of England evidence based guidelines development project: methods of guideline development. BMJ (1996) 5.12
QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br Heart J (1990) 4.28
The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion. Cardiovasc Res (1988) 3.98
Side effects of long-term amiodarone therapy. Circulation (1983) 3.03
Fatal overdosage with disopyramide. Lancet (1978) 2.96
Smoking and decreased fertilisation rates in vitro. Lancet (1992) 2.92
QT prolongation and sudden cardiac death in patients with alcoholic liver disease. Lancet (1993) 2.73
Developing valid guidelines: methodological and procedural issues from the North of England Evidence Based Guideline Development Project. Qual Health Care (1996) 2.49
Purchasing 'legal highs' on the Internet--is there consistency in what you get? QJM (2010) 2.43
Amiodarone pharmacokinetics. Am Heart J (1983) 2.42
Blindness in the Luapula valley. Cent Afr J Med (1967) 2.32
Tissue artefacts caused by sponges. J Clin Pathol (1992) 2.23
Importance of lead selection in QT interval measurement. Am J Cardiol (1988) 2.23
Comparison of two strategies for myocardial management during coronary artery operations. Ann Thorac Surg (1994) 2.21
Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in haemochromatosis. Nat Genet (1999) 2.06
Measuring brain natriuretic peptide. Lancet (1996) 2.03
The apex cardiogram and its relationship to haemodynamic events within the left heart. Br Heart J (1965) 2.02
Oral mexiletine in high-risk patients after myocardial infarction. Lancet (1981) 1.91
The disease complex of the gypsy moth. I. Major components. J Invertebr Pathol (1971) 1.87
Clinical staging in Reye syndrome. Am J Dis Child (1974) 1.84
Delays to thrombolysis in the treatment of myocardial infarction. J R Coll Physicians Lond (1993) 1.75
Hereditary hemochromatosis: gene discovery and its implications for population-based screening. JAMA (1998) 1.73
QT dispersion in sinus beats and ventricular extrasystoles in normal hearts. Br Heart J (1992) 1.70
QT dispersion. Br Heart J (1994) 1.62
Evaluation of fetal arrhythmias by echocardiography. Br Heart J (1983) 1.59
Molecular medicine and hemochromatosis: at the crossroads. Gastroenterology (1999) 1.58
Focal changes in nerve, muscle and connective tissue in normal and unstable human bladder. BJU Int (1999) 1.55
Increased plasma endothelin levels in angina patients with rapid coronary artery disease progression. Eur Heart J (2001) 1.54
Sequence of epicardial repolarisation and configuration of the T wave. Br Heart J (1988) 1.53
Reduction in QT dispersion by sotalol following myocardial infarction. Eur Heart J (1991) 1.50
Bacteroides fragilis resistant to metronidazole after long-term therapy. Lancet (1978) 1.49
A survey of phlebotomy among persons with hemochromatosis. Transfusion (1999) 1.49
Simple bioequivalence criteria: are they relevant to critical dose drugs? Experience gained from cyclosporine. Ther Drug Monit (1997) 1.48
TGF-beta quantitation can be tricky. Transplantation (1999) 1.47
The natural history of chronic pyelonephritis in the adult. Q J Med (1982) 1.47
Errors in manual measurement of QT intervals. Br Heart J (1994) 1.47
Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J (1998) 1.44
Drug therapy for coronary heart disease: the Sheffield table. Lancet (1998) 1.43
HFE S65C variant is not associated with increased transferrin saturation in voluntary blood donors. Blood Cells Mol Dis (2000) 1.42
Attaining United States and European guideline LDL-cholesterol levels with simvastatin in patients with coronary heart disease (the GOALLS study). Curr Med Res Opin (2000) 1.42
Comparison of Nottingham Health Profile (NHP) scores with exercise duration and measures of ischaemia during treadmill exercise testing in patients with coronary artery disease. Eur Heart J (1995) 1.41
Rescue thrombolysis: alteplase as adjuvant treatment after streptokinase in acute myocardial infarction. Br Heart J (1995) 1.40
Evaluation of antiarrhythmic drug efficacy in patients with an ICD: unlimited potential or replete with complexity and problems? J Cardiovasc Electrophysiol (1999) 1.39
The response of paediatric arrhythmias to intravenous and oral flecainide. Br Heart J (1987) 1.39
ECG for physicians: Brugada syndrome. Resuscitation (2006) 1.39
A survey of 2,851 patients with hemochromatosis: symptoms and response to treatment. Am J Med (1999) 1.39
Garland pattern post-streptococcal glomerulonephritis. Nephrol Dial Transplant (1992) 1.39
A controlled trial of substrate-enhanced, warm reperfusion ("hot shot") versus simple reperfusion. Ann Thorac Surg (2000) 1.38
Association between impaired glucose tolerance and circulating concentration of Lp(a) lipoprotein in relation to coronary heart disease. BMJ (1993) 1.38
ESCWGA/NASPE/P experts consensus statement: living anatomy of the atrioventricular junctions. A guide to electrophysiologic mapping. Working Group of Arrhythmias of the European Society of Cardiology. North American Society of Pacing and Electrophysiology. J Cardiovasc Electrophysiol (1999) 1.37
The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med (2009) 1.36
Primary biliary cirrhosis, cutaneous capillaritis, and IgM-associated membranous glomerulonephritis. Br Med J (1977) 1.34
Pacemaker-induced superior vena cava syndrome: report of four cases and review of the literature. Pacing Clin Electrophysiol (1989) 1.33
High-performance liquid chromatographic measurement of amiodarone and its desethyl metabolite: methodology and preliminary observations. Ther Drug Monit (1982) 1.31
Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med (1998) 1.28
Rapid high-performance liquid chromatographic method for the measurement of verapamil and norverapamil in blood plasma or serum. J Chromatogr (1981) 1.26
Comparison of procainamide and mexiletine in prevention of ventricular arrhythmias after acute myocardial infarction. Lancet (1975) 1.25
The haemolytic uraemic syndrome--a family study. Q J Med (1975) 1.25
Measurement of the QT interval. Eur Heart J (1985) 1.25
QT dispersion and components of the QT interval in ischaemia and infarction. Br Heart J (1995) 1.24
Lyme disease and glomerulonephritis. Ir Med J (1999) 1.23
Paediatric use of mexiletine and disopyramide. Br Med J (1979) 1.23
Amiodarone in testis and semen. Lancet (1985) 1.20
Efficacy of new 5-nitroimidazoles against metronidazole-susceptible and -resistant Giardia, Trichomonas, and Entamoeba spp. Antimicrob Agents Chemother (1999) 1.19
Buying 'legal' recreational drugs does not mean that you are not breaking the law. QJM (2010) 1.19
Evaluation of the left ventricle in patients with mitral stenosis. Circulation (1966) 1.18
Atrial fibrillation in the preexcitation syndrome. Am J Cardiol (1977) 1.18
Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit (2001) 1.17
Ventricular arrhythmias in first 12 hours of acute myocardial infarction. Natural history study. Br Heart J (1981) 1.13
Cryosurgical ablation of accessory atrioventricular connections: a method for correction of the pre-excitation syndrome. Circulation (1977) 1.12
Life at a price: the implantable defibrillator. Br Heart J (1990) 1.12
Death rate from use of ecstasy or heroin. Lancet (2000) 1.12
Plasma digoxin: assay anomalies in Fab-treated patients. Br J Clin Pharmacol (1983) 1.12
The Boerhaave syndrome (spontaneous rupture of the oesophagus). Br J Surg (1972) 1.11
Neuropathy and fatal hepatitis in a patient receiving amiodarone. Br Med J (Clin Res Ed) (1984) 1.11
Amiodarone in pregnancy. Lancet (1983) 1.11
Renal biopsy appearances in rheumatoid disease. Clin Nephrol (1983) 1.09
Use of 24 h ambulatory ECG recordings in the assessment of new chemical entities in healthy volunteers. Br J Clin Pharmacol (1995) 1.07
Postmortem assay of digoxin by radioimmunoassay. J Clin Pathol (1975) 1.06
Medical and legal confusion surrounding gamma-hydroxybutyrate (GHB) and its precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4BD). QJM (2008) 1.05
Kinky hair syndrome: serial study of radiological findings with emphasis on the similarity to the battered child syndrome. Radiology (1974) 1.05
Nephrotic syndrome and renal impairment associated with fenclofenac. Ann Rheum Dis (1984) 1.05
Haematuria in rheumatoid arthritis: an association with mesangial glomerulonephritis. Ann Rheum Dis (1984) 1.05
Ventricular arrhythmias in syndrome of balloon deformity of mitral valve. Definition of possible high risk group. Br Heart J (1976) 1.04
An attempt to demonstrate cell migration from the zona glomerulosa in the prepubertal male rat adrenal cortex. J Endocrinol (1973) 1.03
Comparison of four techniques for recognition of ventricular fibrillation from the surface ECG. Med Biol Eng Comput (1993) 1.02
Amiodarone pharmacokinetics. Br J Clin Pract Suppl (1986) 1.02
Rapid high-performance liquid chromatographic method for the measurement of amiodarone in blood plasma or serum at the concentrations attained during therapy. J Chromatogr (1980) 1.02
Clinical features of genetic hemochromatosis in women compared with men. Ann Intern Med (1997) 1.02
Therapeutic monitoring of mycophenolic acid. A consensus panel report. Clin Biochem (1998) 1.01